Aquinox Pharmaceuticals (AQXP) Getting Somewhat Positive Press Coverage, Report Finds

Press coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has been trending somewhat positive recently, according to AlphaOne. The research firm, a unit of Accern, identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a news sentiment score of 0.19 on AlphaOne’s scale. AlphaOne also gave media stories about the company an impact score of 38 out of 100, meaning that recent media coverage is unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have impacted AlphaOne Sentiment’s rankings:

AQXP has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Saturday, March 11th. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Tuesday, March 14th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.80.

Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 4.05% during trading on Friday, reaching $14.92. The company’s stock had a trading volume of 70,014 shares. The firm’s 50-day moving average price is $14.77 and its 200 day moving average price is $15.87. The company’s market capitalization is $349.47 million. Aquinox Pharmaceuticals has a 12-month low of $6.01 and a 12-month high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.15. During the same quarter in the previous year, the firm earned ($0.39) EPS. On average, analysts predict that Aquinox Pharmaceuticals will post ($2.05) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

12 Month Chart for NASDAQ:AQXP

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply